Drug Approval | September 22, 2024
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Fermenta Biotech’s API manufacturing facility receives EU GMP compliance certificate
This license will enable Abbott to enhance access to this novel therapy to more patients across India
ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Subscribe To Our Newsletter & Stay Updated
